Stock Analiz

Kymera Therapeutics, Inc. (KYMR) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Kymera Therapeutics’s revenue went from $3M in fiscal 2019 to $39M in fiscal 2025, growth of about 54.0% a year.

Net income in fiscal 2025 was -$311M, a net margin of -794.0%; the best year in this period was 2019 with -$41M.

Over the twelve months to September 30, 2026, revenue was $102M and net income -$349M.

Free cash flow was -$234M in fiscal 2025 and positive in 2 of the 7 years shown.

The diluted share count rose 4874% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $3M20192020: $34M20202021: $73M20212022: $47M20222023: $79M20232024: $47M20242025: $39M2025$39M
Net income
2019: -$41M20192020: -$46M20202021: -$100M20212022: -$155M20222023: -$147M20232024: -$224M20242025: -$311M2025-$311M
Free cash flow
2019: $17M20192020: $79M20202021: -$131M20212022: -$156M20222023: -$137M20232024: -$207M20242025: -$234M2025-$234M
EPS (diluted)
2019: $-24.2820192020: $-3.1520202021: $-2.0920212022: $-2.8720222023: $-2.5220232024: $-2.9820242025: $-3.692025$-3.69

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$102M$39M$47M$79M$47M$73M$34M$3M
Gross profit$0$0$0$0$0———
Operating income-$405M-$349M-$262M-$166M-$161M-$101M-$46M-$42M
Net income-$349M-$311M-$224M-$147M-$155M-$100M-$46M-$41M
EPS (diluted)$-3.63$-3.69$-2.98$-2.52$-2.87$-2.09$-3.15$-24.28
R&D$430M$317M$240M$189M$164M$137M$62M$37M
Revenue growth—−16.7%−40.1%+67.8%−35.7%+114.0%+1060.0%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow-$288M-$233M-$195M-$103M-$153M-$129M$88M$18M
Capital spending-$1M-$1M-$13M-$34M-$3M-$2M-$9M-$532000
Free cash flow-$289M-$234M-$207M-$137M-$156M-$131M$79M$17M
Dividends paid—$0$0$0$0$0$0$0
Buybacks————————
Stock-based pay$68M$60M$55M$43M$35M$25M$5M$1M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$848M$489M$375M$407M$442M$296M$92M
Debt—$79M$84M$82M$15M$16M$17M$19M
Equity—$1.6B$836M$395M$490M$460M$284M-$74M
Total assets—$1.7B$978M$576M$603M$606M$487M$117M
Shares (diluted)100M84M75M58M54M48M17M2M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin—0.0%0.0%0.0%0.0%———
Operating margin-396.0%-891.1%-555.8%-210.6%-344.4%-138.0%-136.1%-1438.5%
Net margin-341.8%-794.0%-475.6%-187.0%-330.6%-137.6%-134.0%-1405.8%
FCF margin-282.6%-597.6%-440.5%-174.7%-333.0%-179.2%232.2%592.1%
ROIC—-21.1%-22.5%-27.4%-25.2%-16.7%-12.2%—
ROE—-19.7%-26.8%-37.2%-31.6%-21.8%-16.1%55.4%

Frequently asked questions

What is Kymera Therapeutics’s annual revenue?

$39M in fiscal 2025 and $102M over the twelve months to September 30, 2026.

How much profit does Kymera Therapeutics make?

Net income was -$311M in fiscal 2025 (net margin -794.0%).

Is Kymera Therapeutics’s revenue growing?

No: revenue fell 16.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.